Regístrese
Buscar en
Anales de Pediatría Continuada
Toda la web
Inicio Anales de Pediatría Continuada Tumores sólidos más frecuentes en la infancia
Información de la revista
Vol. 2. Núm. 3.
Páginas 153-162 (Enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. 3.
Páginas 153-162 (Enero 2004)
DOI: 10.1016/S1696-2818(04)71635-2
Acceso a texto completo
Tumores sólidos más frecuentes en la infancia
Visitas
72552
Luis Sierrasesumaga
Departamento de Pediatría. Clínica Universitaria. Facultad de Medicina. Universidad de Navarra. Pamplona. España.
Este artículo ha recibido
72552
Visitas
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
L.A.G. Ries, M.A. Smith, J.G. Gurney, M. Linet, T. Tamra, J.L. Young, et al.
Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995,
[2.]
P. Kleihues, W.K. Cavenee.
Pathology and genetics of tumours of the nervous system, pp. 208-241
[3.]
I.F. Pollack, R.L. Hamilton, J. Burham, E.J. Holmes, S.D. Finkelstein, R. Sposto, et al.
Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Neurosurgery, 50 (2002), pp. 1238-1244
[4.]
G.J. Lesser.
Chemotherapy of low grade gliomas.
Semin Radiat Oncol, 11 (2001), pp. 138-144
[5.]
J.H. Wisoff, J.M. Boyett, M.S. Berger, C. Brant, H. Li, A.J. Yates, et al.
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG–945.
J Neurosurg, 90 (1999), pp. 52-59
[6.]
C. Kalifa, D. Valteau, B. Pizer, G. Vassal, J. Grill, O. Hatrmann.
High dose chemotherapy in childhood brain tumours.
Child Nerv Syst, 15 (1999), pp. 498-505
[7.]
P.K. Duffner, J.P. Krischer, P.C. Burger, M.E. Cohen, J.W. Backstrom, M.E. Horowitz, et al.
Treatment of infants with malignant gliomas: the POG experience.
J Neurooncol, 28 (1996), pp. 245-256
[8.]
J.C. Nicholson, F.M. Ross, J.A. Kohler, D.W. Ellison.
Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours.
Br J Cancer, 80 (1999), pp. 1322-1331
[9.]
R.J. Packer, J. Goldwein, H.S. Nicholson, L.G. Vezina, J.C. Allen, M.D. Ris, et al.
Treatment of children with medulloblastoma with reduced dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Study Group.
J Clin Oncol, 17 (1999), pp. 2127-2136
[10.]
P.K. Duffner, M.E. Horowitz, J.P. Krischer, H.S. Friedman, P.C. Burger, M.E. Cohen, et al.
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
N Engl J Med, 328 (1993), pp. 1725-1731
[11.]
D.R. Copeland, C. DeMoor, I.I.I. Moore BD, J.L. Ater.
Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study.
J Clin Oncol, 17 (1999), pp. 3476-3486
[12.]
R.I. Jakacki, P.M. Zeltzer, J.M. Boyett, A.L. Albright, J.C. Allen, J.R. Geyer, et al.
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
J Clin Oncol, 13 (1995), pp. 1377-1383
[13.]
A.T. Reddy, A.J. Janss, P.C. Phillips, H.L. Weiss, R.J. Packer.
Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy.
Cancer, 88 (2000), pp. 2189-2193
[14.]
D. Strother, D. Ashley, S.J. Kellie, A. Patel, D. Jones-Wallace, S. Thompson, et al.
Feasibility of four consecutive high-dose chemotherapy cycles with stem cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
J Clin Oncol, 15 (2001), pp. 2696-2704
[15.]
C.R. Freeman, J.P. Farmer.
Pediatric brain stem gliomas: a review.
Int J Radiation Oncol Biol Phys, 40 (1998), pp. 265-271
[16.]
C.R. Freeman, J. Kneper, L.E. Kun, R.A. Sandford, R. Kadota, L. Mandell, et al.
A detrimental effect of a combained chemotherapy- radiotherapy approach in children with diffuse intrinsic brain stem gliomas.
Int J radiation Oncol Biol Phys, 47 (2000), pp. 561-564
[17.]
H. Ikeda, T. Lehara, Y. Tsuchida, M. Kaneko, J. Hata, H. Naito, et al.
Experience with International Neuroblastoma Staging System and Pathology Classification.
Br J Cancer, 86 (2002), pp. 1110-1116
[18.]
S.J. Cotterill, A.D. Pearson, J. Pritchard, A.B. Foot, B. Roald, J.A. Kohler, et al.
Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group “Survey” 1982–1992.
Eur J Cancer, 36 (2000), pp. 901-908
[19.]
M.L. Schmidt, J.N. Lukens, R.C. Seeger, G.M. Brodeur, H. Shimada, R.B. Gerbing, et al.
Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study.
J Clin Oncol, 18 (2000), pp. 1260-1268
[20.]
C. Poremba, B. Hero, H.G. Goertz, C. Scheel, D. Wai, K.L. Schaefer, et al.
Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.
Klin Padiatr, 213 (2001), pp. 186-190
[21.]
M. Lastowska, C. Cullinane, S. Variend, S. Cotterill, N. Bown, S. O'Neill, et al.
Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.
J Clin Oncol, 19 (2001), pp. 3080-3090
[22.]
K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, R.K. Ramsay, et al.
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
N Engl J Med, 341 (1999), pp. 1165-1173
[23.]
C. Mitchell, P.M. Jones, A. Kelsey, G.M. Vujanic, B. Marsden, R. Shannon, et al.
The treatment of Wilms' tumour: results of the United Kingdom Children's cancer study group (UKCCSG) second Wilms' tumour study.
Br J Cancer, 83 (2000), pp. 602-608
[24.]
L. Diller, M. Ghahremani, J. Morgan, P. Grundy, C. Reeves, N. Breslow, et al.
Constitutional WT1 mutations in Wilms' tumor patients.
J Clin Oncol, 16 (1998), pp. 3634-3640
[25.]
J.B. Beckwith.
Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations.
Am J Med Genet, 79 (1998), pp. 268-273
[26.]
G.M. Vujanic, D. Harms, B. Sandstedt, A. Weirich, J. De Kraker, J.F. Delemarre.
New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
Med Pediatr Oncol, 32 (1999), pp. 317-323
[27.]
J.A. Meisel, K.A. Guthrie, N.E. Breslow, S.S. Donaldson, D.M. Green.
Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group.
Int J Radiat Oncol Biol Phys, 44 (1999), pp. 579-585
[28.]
D.M. Green, N.E. Breslow, J.B. Beckwith, J.Z. Finklestein, P.E. Grundy, P.R. Thomas, et al.
Comparison between singledose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
J Clin Oncol, 16 (1998), pp. 237-245
[29.]
D.M. Green, N.E. Breslow, J.B. Beckwith, J.Z. Finklestein, P.E. Grundy, P.R. Thomas, et al.
Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.
J Clin Oncol, 16 (1998), pp. 3744-3751
[30.]
L. Diller, E. Sexsmith, A. Gottlieb, F.P. Li, D. Malkin.
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
J Clin Invest, 95 (1995), pp. 1606-1611
[31.]
J.G. Gurney, J.r. Young JL, S.D. Roffers, et al.
Soft tissue sarcomas.
Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, pp. 111-124
[32.]
D.M. Parham.
Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.
Mod Pathol, 14 (2001), pp. 506-514
[33.]
P.H. Sorensen, J.C. Lynch, S.J. Qualman, R. Tirabosco, J.F. Lim, M.H. Maurer, et al.
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
J Clin Oncol, 20 (2002), pp. 2672-2679
[34.]
R.B. Raney, J.R. Anderson, F.G. Barr, S.S. Donaldson, A.S. Pappo, S.J. Qualman, et al.
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
J Pediatr Hematol Oncol, 23 (2001), pp. 215-220
[35.]
J.r. Lawrence W, J.R. Anderson, E.A. Gehan, H. Maurer.
Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group.
Cancer, 80 (1997), pp. 1165-1170
[36.]
J.C. Breneman, E. Lyden, A.S. Pappo, M.P. Link, J.R. Anderson, D.M. Parham, et al.
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma. a report from the Intergroup Rhabdomyosarcoma Study IV.
J Clin Oncol, 21 (2003), pp. 78-84
[37.]
W.M. Crist, J.R. Anderson, J.L. Meza, C. Fryer, R.B. Raney, F.B. Ruymann, et al.
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
J Clin Oncol, 19 (2001), pp. 3091-3102
[38.]
M.P. Link, M.C. Gebhart, P.A. Meyers.
Osteosarcoma.
Principles and practice of pediatric oncology, 4th ed, pp. 1051-1089
[39.]
J.P. Ginsberg, S.Y. Woo, M.E. Johnson, M.E. Hicks, M.E. Horowitz.
Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors.
Principles and practice of pediatric oncology, 4th ed, pp. 973-1016
[40.]
M.D. Tabone, P. Terrier, H. Pacquement, M. Brunat, C. Smchmitt, A. Babin, et al.
Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases.
J Clin Oncol, 17 (1999), pp. 2789-2795
[41.]
E. De Alava, A. Kawai, J.H. Healey, I. Fligman, P.A. Meyers, A.G. Huvos, et al.
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
J Clin Oncol, 16 (1998), pp. 1248-1255
[42.]
S.S. Bielack, B. Kempf-Bielack, G. Delling, G.U. Exner, S. Flege, K. Helmke, et al.
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.
J Clin Oncol, 20 (2002), pp. 776-790
[43.]
H.E. Grier, M.D. Krailo, N.J. Tarbell, M.P. Link, C.J. Fryer, D.J. Pritchard, et al.
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
N Engl J Med, 348 (2003), pp. 694-701
[44.]
E.A. Kolb, B.H. Kushner, R. Gorlick, C. Laverdiere, J.H. Healey, M.P. LaQuaglia, et al.
Long-term event free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
J Clin Oncol, 21 (2003), pp. 3423-3430
[45.]
J.A. Ortega, E.C. Douglass, J.H. Feusner, M. Reynolds, J.J. Quinn, M.J. Finegolg, et al.
Randomized comparison of cisplatin/vincristine/ fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group.
J Clin Oncol, 18 (2000), pp. 2665-2675
[46.]
H.M. Katzenstein, M.D. Krailo, M.H. Malogolowkin, J.A. Ortega, W. Liu-Mares, E.C. Douglass, et al.
Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
J Clin Oncol, 20 (2002), pp. 2789-2797
[47.]
B. Cushing, E.J. Perlman, N.M. Marina, R.P. Castleberry.
Germ cell tumors.
Principles and practice of pediatric oncology, 4th ed, pp. 1091-1114
[48.]
C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstric, J. Beyer, B. Metzner, et al.
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis.
J Clin Oncol, 17 (1999), pp. 3450-3456
[49.]
S. Bhatia, R. Abonour, P. Porcu, R. Seshadri, C.R. Nichols, K. Cornetta, et al.
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer.
J Clin Oncol, 18 (2000), pp. 3346-3351
[50.]
R.J. Motzer, M. Mazumdar, J. Sheinfeld, D.F. Bajorin, H.A. Macapinlac, M. Bains, et al.
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
J Clin Oncol, 18 (2000), pp. 1173-1180
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.